New research predicts that the U.S. will spend almost $2 billion in 2016 on cancer drugs that ultimately go to waste.
A genomic assay may help oncologists determine whether certain patients actually need adjuvant therapy, according to recent study.
Is there a benefit to using aromatase inhibitor (AI) therapy after 5 years? Experts discuss the evidence.
Researchers have proposed a new standard of care for older, fit patients with secondary acute myeloid leukemia, based on the results of a Phase III trial that showed a survival benefit in this population.
A new white paper details a roadmap for melanoma care based on the most up-to-date evidence on prevention, diagnosis, and treatment.
The Clin Onc News Report is brought to MedPage Today readers by our friends at Clinical Oncology News, a McMahon Group title. Free registration required for some articles.
Pricey Drugs Going to Waste: The Clin Onc News Report
Aucun commentaire:
Enregistrer un commentaire